Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [31] RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
    Alvaro Moreno-Aspitia
    Amylou C. Dueck
    Ismael Ghanem-Cañete
    Tejal Patel
    Shaker Dakhil
    David Johnson
    Sandra Franco
    Stephen Kahanic
    Gerardo Colon-Otero
    Kathleen S. Tenner
    Richard Rodeheffer
    Ann E. McCullough
    Robert B. Jenkins
    Frances M. Palmieri
    Donald Northfelt
    Edith A. Perez
    Breast Cancer Research and Treatment, 2013, 138 : 427 - 435
  • [32] Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
    Wang, Xiaojia
    Li, Wei
    Yin, Yongmei
    Tong, Zhongsheng
    Zhang, Qingyuan
    Zheng, Hong
    Shao, Zhimin
    Li, Huiping
    Yang, Jin
    Feng, Jifeng
    Wu, Fan
    Lamour, Francois
    Restuccia, Eleonora
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [33] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [34] Costs of intravenous vs. subcutaneous administration of trastuzumab in peruvian patients with HER2-positive breast cancer - An observational analysis of direct and indirect costs
    Changra, Henry Olivera
    Diaz, Jose Fernando Robles
    JOURNAL OF HEALTHCARE QUALITY RESEARCH, 2022, 37 (03) : 147 - 154
  • [35] Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)
    Schmidt, Marcus
    Kuemmel, Sherko
    Ruf-Doerdelmann, Antonia
    Distelrath, Andrea
    Wacker, Juergen
    Schmatloch, Sabine
    Busch-Liles, Saskia
    Luedtke-Heckenkamp, Kerstin
    ANTICANCER RESEARCH, 2021, 41 (01) : 485 - 496
  • [36] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
    Andras Nagy
    Kimberly Duff
    Alexander Bauer
    Fred Okonneh
    Juan Carlos Rondon
    Leman Yel
    Zhaoyang Li
    Journal of Clinical Immunology, 2024, 44
  • [37] Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study
    Li, Yinjuan
    Qi, Lu
    Wang, Yu
    Zhao, Xia
    Lv, Shuzhen
    Feng, Yu
    Liu, Chen
    Li, Pu
    Xiong, Bingjun
    Guo, Yihui
    Lv, Dapeng
    Liu, Yongbo
    Mao, Ting
    Yuan, Keyu
    Cheng, Xiaoqiang
    Li, Yanping
    Wang, Xinghe
    ANTI-CANCER DRUGS, 2023, 34 (06) : 763 - 774
  • [38] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
    Nagy, Andras
    Duff, Kimberly
    Bauer, Alexander
    Okonneh, Fred
    Rondon, Juan Carlos
    Yel, Leman
    Li, Zhaoyang
    JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (01)
  • [39] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
    Pivot, X.
    Bondarenko, I.
    Nowecki, Z.
    Dvorkin, M.
    Trishkina, E.
    Ahn, J. -H.
    Im, S. -A.
    Sarosiek, T.
    Chatterjee, S.
    Wojtukiewicz, M. Z.
    Shparyk, Y.
    Moiseyenko, V.
    Bello, M., III
    Semiglazov, V.
    Lee, Y.
    Lim, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 93 : 19 - 27
12345